» Articles » PMID: 17259947

Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events

Overview
Publisher Wiley
Specialty Pharmacology
Date 2007 Jan 30
PMID 17259947
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Duplications and multiplications of active CYP2D6 genes can cause ultrarapid drug metabolism and lead to therapeutic failure. Multiple functional and non-functional duplication alleles have been further characterized. Duplications were detected by long-range polymerase chain reaction (PCR), PCR-restriction fragment length polymorphism, and sequence analysis. A PCR fragment encompassing the entire duplicated gene was utilized for detailed characterization. Duplications occurred at 1.3, 5.75, and 2.0% in Caucasian, African American, and racially mixed populations, respectively (n=887 total). Of those 28, 47, and 17% were non-functional CYP2D6*4 x N. Twelve unique duplication alleles were detected: *1 x N, *2 x N, *4 x N, *6 x N, *10 x N, *17 x N, *17 x N[spacer], *29 x N, *35 x N, *43 x N, *45 x N, and a novel non-functional tandem arrangement of a chimeric 2D7/2D6 and *1 gene. All novel duplications except *35 x N were found in African Americans. Accurate identification of gene duplication events is essential to avoid false-positive ultrarapid metabolism assignments and thus, overestimation of predicted activity and increased risk for unwanted adverse events.

Citing Articles

Nanopore sequencing-based genotyping suggested an association between CYP2D6 function and susceptibility to anxiety and depression.

Chua E, Karunanathie H, Yanasegaran K, Maggo S, Kee P, Kennedy M BMC Res Notes. 2025; 18(1):88.

PMID: 40016731 PMC: 11869584. DOI: 10.1186/s13104-025-07156-9.


Applications of genome sequencing as a single platform for clinical constitutional genetic testing.

Yang Y, Del Gaudio D, Santani A, Scott S Genet Med Open. 2025; 2():101840.

PMID: 39822265 PMC: 11736070. DOI: 10.1016/j.gimo.2024.101840.


Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.

DCunha R, Azam T, Kalabic J, Anschutz T, Lahat A, Pang Y Clin Pharmacokinet. 2024; 64(1):143-154.

PMID: 39707077 PMC: 11762434. DOI: 10.1007/s40262-024-01462-4.


Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences.

Sherman C, Claw K, Lee S Sci Rep. 2024; 14(1):22774.

PMID: 39354004 PMC: 11445439. DOI: 10.1038/s41598-024-73748-3.


PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting.

Turner A, Nofziger C, Ramey B, Ly R, Bousman C, Agundez J Clin Pharmacol Ther. 2023; 114(6):1220-1237.

PMID: 37669183 PMC: 10840842. DOI: 10.1002/cpt.3044.